REG - CVS Group plc - Transaction in Own Shares

CVSAnnouncement

17/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251217:nRSQ8349La&default-theme=true

RNS Number : 8349L  CVS Group plc  17 December 2025

17 December 2025

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

 

CVS announces that on 16 December 2025 it purchased the following number of
its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg,
Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the
terms of the share buyback programme announced on 24 October 2025 (the "Share
Buyback Programme").

 

 Date of purchase:                                    16/12/2025
 Aggregate number of Ordinary Shares purchased:       4,432
 Lowest price paid per share (GBp):                   1,228.00
 Highest price paid per share (GBp):                  1,248.00
 Volume weighted average price paid per share (GBp):  1,240.57

CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary
Shares purchased, CVS will have 70,821,122 Ordinary Shares in issue and holds
no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 70,821,122 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has
repurchased 919,661 Ordinary Shares in aggregate at a weighted average price
of 1,216.05 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, the table below contains detailed
information of the individual trades made by Berenberg as part of the Share
Buyback Programme.

 

Individual transactions:

 

 Number of                   Transaction price (GBp share)  Time of                 Transaction        Trading Venue

 Ordinary Shares purchased                                  transaction (UK Time)   reference number

 237                         1228                           16/12/2025 08:27:01     1352700633551196   XLON
 630                         1230                           16/12/2025 11:21:09     1352700633561715   XLON
 636                         1236                           16/12/2025 13:53:15     1352700633570871   XLON
 474                         1242                           16/12/2025 14:26:54     1352700633573429   XLON
 289                         1242                           16/12/2025 14:26:54     1352700633573436   XLON
 93                          1244                           16/12/2025 14:59:42     1352700633578048   XLON
 11                          1244                           16/12/2025 15:28:59     1352700633582307   XLON
 143                         1244                           16/12/2025 15:38:33     1352700633583474   XLON
 74                          1244                           16/12/2025 15:38:33     1352700633583476   XLON
 13                          1242                           16/12/2025 15:56:59     1352700633586344   XLON
 48                          1242                           16/12/2025 15:56:59     1352700633586345   XLON
 137                         1242                           16/12/2025 15:56:59     1352700633586346   XLON
 137                         1242                           16/12/2025 15:56:59     1352700633586347   XLON
 26                          1242                           16/12/2025 15:56:59     1352700633586348   XLON
 198                         1242                           16/12/2025 16:08:52     1352700633589090   XLON
 35                          1248                           16/12/2025 16:27:25     1352700633593369   XLON
 110                         1248                           16/12/2025 16:27:25     1352700633593368   XLON
 6                           1248                           16/12/2025 16:27:25     1352700633593370   XLON
 260                         1248                           16/12/2025 16:27:25     1352700633593372   XLON
 83                          1248                           16/12/2025 16:27:25     1352700633593371   XLON
 396                         1248                           16/12/2025 16:27:32     1352700633593429   XLON
 198                         1248                           16/12/2025 16:27:32     1352700633593428   XLON
 198                         1248                           16/12/2025 16:27:32     1352700633593430   XLON

 

 

Contacts

CVS Group
plc
via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint Broker)
 
           +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint
Broker)
                +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial PR)
 
                                   cvsg@camarco.co.uk

Ginny
Pulbrook
+44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia.  CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSGPGUUPUPAGRQ



            Copyright 2019 Regulatory News Service, all rights reserved